Compare Heron Therapeutics Inc (HRTX) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.35 (market cap $28.50B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 419.1× Heron Therapeutics Inc's market cap, and iShares iBoxx $ Inv Grade Corporate Bond ETF is more actively traded (37,320,110 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| HRTX | LQD | |
|---|---|---|
Market Cap | $68.01M | $28.50B |
Volume | 1,891,941 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $112.91 |
52-Week Low | $0.27 | $101.83 |
Typical Hold Time | 35 Days | 125 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $102.12 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators suggest potential stabilization. The ETF faces headwinds from rising Treasury yields and increased short interest, which grew 53.1% in September 2026. Recent dividend payments of $0.44-$0.46 provide income support amid market volatility.
The outlook remains cautious as higher interest rates pressure corporate bond valuations. Investment opportunities exist for income-focused investors seeking quality credit exposure, but risks include continued bond market selloffs and economic uncertainty. The ETF's 4.8% yield and investment-grade portfolio offer defensive characteristics, though duration risk persists with its 7.7-year average maturity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
